Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
By Editorial Team
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, has recently announced the issuance of a new patent in the U.S., US Patent Number 12,496,345, titled "A Method of Treating Cancer." This new patent strengthens the company's existing intellectual property portfolio, which now includes patents granted in 41 countries to protect its novel intratumoral technology, including the lead compound INT230-6.
Significance of the New Patent
Lewis H. Bender, Founder, President & CEO of Intensity Therapeutics, highlighted the importance of the new patent, stating that it supports the uniqueness of their technology not only in the U.S. but also globally. The company now holds four U.S. patents and one pending U.S. patent application, along with protection in 41 countries, including a European patent validated in 27 countries.
Intellectual Property Portfolio Details
Intensity Therapeutics boasts a robust intellectual property position with a total of 19 issued patents, including four in the U.S. The company can enforce its patent claims in various countries, covering major pharmaceutical markets worldwide. The recently issued U.S. patents focus on methods of treating cancer and intratumoral formulations, with expiration dates extending to 2033.
The company has also received Orphan drug status for the components of INT230-6, providing additional market exclusivity post-approval. Intensity Therapeutics has pursued patent prosecution in key markets globally, including Australia, China, Japan, and several European countries.
About INT230-6
INT230-6 is Intensity's lead proprietary investigational product designed for direct intratumoral injection. Developed using the company's DfuseRx℠ technology platform, INT230-6 comprises two potent anti-cancer agents, cisplatin and vinblastine sulfate, along with a cell penetration enhancer molecule. This formulation allows for the dispersion of cytotoxic drugs within tumors, leading to tumor cell death and immune system activation without causing immunosuppression.
About Intensity Therapeutics
Intensity Therapeutics is focused on developing novel cancer therapies that leverage its unique drug-conjugation technology. The company's approach aims to kill tumors and enhance the immune system's ability to recognize cancer cells. Intensity has conducted clinical trials with INT230-6 in various cancer types, demonstrating promising results in terms of tumor regression and immune system activation.
For more information about Intensity Therapeutics and its innovative approach to cancer therapeutics, visit their website at www.intensitytherapeutics.com.
Disclaimer: This article contains forward-looking statements that are subject to risks and uncertainties. Readers are advised to refer to the company's official communications and regulatory filings for accurate and updated information.